IBI308

Phase 1Completed

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Advanced/Metastatic Solid Malignancies

Conditions

Advanced/Metastatic Solid Malignancies

Trial Timeline

Jun 27, 2018 → Dec 7, 2020

NCT ID

NCT03568539

About IBI308

IBI308 is a phase 1 stage product being developed by Innovent Biologics for Advanced/Metastatic Solid Malignancies. The current trial status is completed. This product is registered under clinical trial identifier NCT03568539. Target conditions include Advanced/Metastatic Solid Malignancies.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03568539	Phase 1	Completed	Jun 27, 2018	Dec 7, 2020	Advanced/Metastatic Solid Malignancies

Competing Products

20 competing products in Advanced/Metastatic Solid Malignancies

See all competitors

Product	Company	Stage	Hype Score
Recombinant oncolytic virus M1, anti PD-1 antibody, Apatinib	Sun Pharmaceutical	Phase 1	33
Pembrolizumab + Lenvatinib + Oxaliplatin + Capecitabine + Leucovorin (or Levoleucovorin) + 5-FU	Eisai	Phase 3	77
PF-05082566 + KW-0761	Kyowa Kirin	Phase 1	33
eftilagimod alfa + carboplatin plus paclitaxel + cisplatin or carboplatin + pemetrexed + pembrolizumab (KEYTRUDA®)	Merck	Phase 3	77
MK-4464 + Pembrolizumab + 89Zr-MK-4464	Merck	Phase 1	33
ADG126 + Pembrolizumab (KEYTRUDA®) + Standard of Care (Trifluridine/Tipiracil-Bevacizumab) + Standard of care (Fruquintinib)	Merck	Phase 1/2	41
Selumetinib + Pembrolizumab	Merck	Phase 1	33
BJ-001 + Pembrolizumab	Merck	Phase 1	33
ADG116	Merck	Phase 1	33
Gebasaxturev IV + Gebasaxturev ITu + Pembrolizumab	Merck	Phase 2	52
ADU-S100 + ipilimumab	Novartis	Phase 1	33
simlukafusp alfa + Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody + Gemcitabine + Vinorelbine	Roche	Phase 2	52
Selicrelumab + Vanucizumab + Bevacizumab	Roche	Phase 1	33
AMG 510	Amgen	Phase 1	32
PF-08634404 + Sigvotatug Vedotin + Combination Agent 1	Pfizer	Phase 1/2	40
PF-08046876	Pfizer	Phase 1	32
Capecitabine + Sunitinib	Pfizer	Phase 2	51
MM-121 + Paclitaxel	Sanofi	Phase 1	32
Ubamatamab + REGN7075 + Sarilumab	Regeneron Pharmaceuticals	Phase 2	51
ALLO-647 + Fludarabine + Cyclophosphamide	Allogene Therapeutics	Phase 1	25

Other Products from Innovent Biologics

Taxane and Carboplatin + Short-term SintilimabApproved

Teprotumumab N01 + MethylprednisoloneApproved

IBI311Phase 3

Febuxostat + TigulixostatPhase 3

IBI301 plus CHOP + Rituximab plus CHOPPhase 3